Ameriprise’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$886K Sell
42,295
-234,632
-85% -$5.28M ﹤0.01% 3355
2025
Q4
$6.37M Buy
276,927
+138,243
+100% +$4.55M ﹤0.01% 2261
2025
Q3
$4.17M Buy
138,684
+29,447
+27% +$883K ﹤0.01% 2564
2025
Q2
$3.97M Buy
109,237
+89,940
+466% +$3.24M ﹤0.01% 2531
2025
Q1
$699K Buy
19,297
+5,901
+44% +$245K ﹤0.01% 3368
2024
Q4
$564K Buy
13,396
+1,039
+8% +$51.5K ﹤0.01% 3483
2024
Q3
$686K Buy
12,357
+578
+5% +$29.4K ﹤0.01% 3370
2024
Q2
$484K Sell
11,779
-1,889
-14% -$80.7K ﹤0.01% 3420
2024
Q1
$638K Buy
13,668
+2,592
+23% +$122K ﹤0.01% 3339
2023
Q4
$530K Sell
11,076
-4,417
-29% -$171K ﹤0.01% 3435
2023
Q3
$552K Sell
15,493
-5,227
-25% -$207K ﹤0.01% 3372
2023
Q2
$956K Sell
20,720
-37,775
-65% -$1.75M ﹤0.01% 3192
2023
Q1
$2.35M Buy
58,495
+20,312
+53% +$872K ﹤0.01% 2769
2022
Q4
$1.77M Buy
38,183
+22,092
+137% +$869K ﹤0.01% 2864
2022
Q3
$667K Buy
16,091
+1,508
+10% +$77.5K ﹤0.01% 3287
2022
Q2
$870K Buy
14,583
+10
+0.1% +$615 ﹤0.01% 3176
2022
Q1
$1.06M Sell
14,573
-346
-2% -$24.1K ﹤0.01% 3192
2021
Q4
$1.25M Buy
14,919
+224
+2% +$18.2K ﹤0.01% 3151
2021
Q3
$1.33M Sell
14,695
-10,365
-41% -$937K ﹤0.01% 3036
2021
Q2
$2.39M Buy
25,060
+848
+4% +$88.3K ﹤0.01% 2855
2021
Q1
$2.75M Sell
24,212
-16,714
-41% -$2.28M ﹤0.01% 2729
2020
Q4
$5.67M Buy
40,926
+17,730
+76% +$2.1M ﹤0.01% 2178
2020
Q3
$1.91M Buy
23,196
+3,529
+18% +$293K ﹤0.01% 2695
2020
Q2
$1.54M Sell
19,667
-6,420
-25% -$425K ﹤0.01% 2730
2020
Q1
$1.16M Buy
26,087
+16,635
+176% +$864K ﹤0.01% 2756
2019
Q4
$402K Sell
9,452
-892,376
-99% -$36.8M ﹤0.01% 3407
2019
Q3
$38.6M Sell
901,828
-15,797
-2% -$858K 0.02% 782
2019
Q2
$58.3M Buy
917,625
+89,865
+11% +$5.72M 0.03% 605
2019
Q1
$57.4M Sell
827,760
-18,712
-2% -$1.07M 0.03% 593
2018
Q4
$36.8M Sell
846,472
-385,801
-31% -$21.1M 0.02% 744
2018
Q3
$94.1M Sell
1,232,273
-99,189
-7% -$8.07M 0.03% 492
2018
Q2
$102M Buy
1,331,462
+132,431
+11% +$8.55M 0.05% 406
2018
Q1
$61.1M Buy
1,199,031
+1,161,985
+3,137% +$58.5M 0.03% 560
2017
Q4
$1.72M Sell
37,046
-9,517
-20% -$467K ﹤0.01% 2732
2017
Q3
$2.48M Sell
46,563
-55,211
-54% -$3.27M ﹤0.01% 2501
2017
Q2
$6.32M Buy
101,774
+7,229
+8% +$436K ﹤0.01% 1899
2017
Q1
$6.41M Sell
94,545
-13,566
-13% -$1.03M ﹤0.01% 1853
2016
Q4
$7.6M Sell
108,111
-65,708
-38% -$4.66M ﹤0.01% 1714
2016
Q3
$12.3M Sell
173,819
-175,434
-50% -$11.2M 0.01% 1286
2016
Q2
$17.1M Buy
349,253
+139,511
+67% +$9.02M 0.01% 1003
2016
Q1
$13.3M Sell
209,742
-260,592
-55% -$17.1M 0.01% 1207
2015
Q4
$52.8M Buy
470,334
+93,380
+25% +$9.34M 0.03% 454
2015
Q3
$36.3M Buy
376,954
+264,457
+235% +$30.3M 0.02% 611
2015
Q2
$11.5M Buy
112,497
+62,197
+124% +$4.83M 0.01% 1465
2015
Q1
$3.12M Buy
50,300
+25,546
+103% +$1.42M ﹤0.01% 2360
2014
Q4
$1.09M Sell
24,754
-21,547
-47% -$987K ﹤0.01% 2846
2014
Q3
$2.62M Sell
46,301
-64,689
-58% -$3.26M ﹤0.01% 2385
2014
Q2
$4.98M Sell
110,990
-49,543
-31% -$2.04M ﹤0.01% 2083
2014
Q1
$7.85M Buy
+160,533
New +$8.26M ﹤0.01% 1713

Other funds holding RARE

Ameriprise's RARE Position: Q1 2026 in Review

Ameriprise reduced its Ultragenyx Pharmaceutical (RARE) stake by 85% in Q1 2026, selling an estimated $5.28M and leaving 42,295 shares worth $886K. The position accounts for ﹤0.01% of the portfolio, ranked #3355.

Ameriprise first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $102M in Q2 2018. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Ameriprise held 42,295 shares of Ultragenyx Pharmaceutical worth $886K as of Q1 2026.
  • Ameriprise sold 234,632 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $5.28M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3355 holding.
  • Ameriprise first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
  • Ameriprise's Ultragenyx Pharmaceutical position peaked at $102M in Q2 2018.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.